releasing factor


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

releasing factor

(rĭ-lē′sĭng)
n.
Any of several hormones secreted by the hypothalamus that stimulate the anterior part of the pituitary gland to release certain hormones.

releasing factor

a special form of REGULATING FACTOR that stimulates the release of hormones into the blood; inhibiting factors prevent the release of the hormone.
References in periodicals archive ?
Hypothalamic cocaine- and amphetamine-regulated transcript and corticotrophin releasing factor neurons are stimulated by extracellular volume and osmotic changes.
Urocortin 2 is associated with abdominal aortic aneurysm and mediates anti-proliferative effects on vascular smooth muscle cells via corticotrophin releasing factor receptor 2.
Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implications.
The company's lead compound, ThGRF, is an analogue of a natural hormone known as growth hormone releasing factor.
Blunted adrenocorticotropin hormone and [Beta]-endorphin responses after corticotropin releasing factor administration
Corticotropin releasing factor (CRF): Studies in alcohol preferring and non-preferring rats.
Theratechnologies submitted an NDA to the FDA on 29 May 2009, for tesamorelin, an analogue of the growth hormone releasing factor, proposed for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy.
Central regulation of gastric emptying of solid nutrient meals by corticotropin releasing factor.
Consumption of alcohol also may alter regulatory agents of stress, particularly increasing corticotropin releasing factor (CRF) activity and decreasing neuropeptide Y.
The name's initial letters also reference ghrelin's role as a growth hormone releasing factor.
Neurogen Corporation (Branford, CT; 203-315-4615), a leading small molecule drug discovery and development company, and Aventis Pharma (Bridgewater, NJ; 908-231-4659), jointly announced an exclusive worldwide collaboration to develop new drugs for treatment of depression, anxiety, and other stress-related disorders based on Neurogen's innovative portfolio of pre-clinical corticotrophin releasing factor (CRF1) antagonist compounds.
The market scenario is expected to change after the launch of new therapies such as Alpha and Beta Adrenergic Receptor antagonists, N - methyl D - aspartate (NMDA) receptor modulators, Corticotropin Releasing Factor (CRF1) inhibitors, Progesterone receptor antagonist, V1 Receptor antagonists, and mGluR7 NAM inhibitor.